CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell su...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Thayaparan, Thivyan, Petrovic, Roseanna M., Achkova, Daniela Y., Zabinski, Tomasz, Davies, David M., Klampatsa, Astero, Parente-Pereira, Ana C., Whilding, Lynsey M., van der Stegen, Sjoukje JC, Woodman, Natalie, Sheaff, Michael, Cochran, Jennifer R., Spicer, James F., Maher, John
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706532/
https://ncbi.nlm.nih.gov/pubmed/29209570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1363137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars